Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ELTP just broke above 10, 50 and 200sma on 5 min chart!!!
Pps just above 200sma on 5min chart!!!!!
Ready to run. 5min chart shows a lot of upside!!!
The smart ones would of said south.
Calm before the storm. Should shoot north soon.
Does it matter? No. He has them and isn't selling them.
I see a nice little run back to the north today. IMO
Daily, 1 hour, and 5 minute charts all are in bull mode. Should be a fun March!!!! IMO.
I see it bouncing off .23 for another run to the north! Love the short medium and long term charts on this stock!!!!
Symmetrical triangle is forming.
5 min candlestick chart says it's time to move north!
You know it! Let the BULLS out!!!!
Makes total sense. The pps is sitting at the 50sma. I see it going north today. IMO.
Looks like it might bounce off the 50 sma.
I agree.
Looking at the 5 min chart this stock has a lot of room to run.
Looks like a doji candle day.
Bet we close green .22 imo.
ELTP on the move up. Broke through resistance points!! FDA filing coming soon!!!
Anyone notice the market makers trying to move the price up?
Resistance at .21. Maybe that is the bottom. I don't know about you but I am ready to head North. GL
Soon to file with the FDA!!!! ELTP filing its first of many Abuse resistance drugs. All trials have been highly successful!! Check it out!!
Maybe it is a sign that it is, "Go Time!"
Someone might know something that we don't, which is fine by me!!
Be greedy when others are fearful! Unless you don't believe what you are investing in? I know I believe.
Who says they haven't?
Found this online. David Ando wrote it. Go eltp!!
ELTP – Elite Pharmaceuticals
I was seeking undervalued companies on the exchange, and I caught this declining bio tech stock in an article highlighting “loser” stocks. Throughout the years of trading I realized that companies that have been hit the hardest have the potential to come back the hardest. I’ve been following this stock for the past three years and I decided to write about why I like it so much.
First of all, the chronic pain market is huge – 24.7 billion annual huge by the year 2017. If they capture 1% of that market, then the eps will be .50 and with a 20 p/e multiple you’re talking about $10.00 per share versus .40 today. The potential is huge and it is within reasonable grasp. There are three major reasons why this drug will take ELTP beyond $10.00 that many people currently watching this stock seem to miss.
Reason 1: Purdue’s Oxycontin patent expiration.
This money making drug made 2.8 billion annually for Purdue. Their patent expired in April of 2013; every drug maker on the planet had this date marked on their calenders. In order for Purdue to protect their Oxycontin sales they “pushed” congress to mandate a safety mechanism in this deadly opiate. “In concert with the White House plan, the Food and Drug Administration (FDA) is announcing a new risk reduction program for all extended-release and long-acting opioid medications” (2013). In order for you to get through the approval door now, you need anti abuse tech, plain and simple. At the same time, Purdue pushes their “abuse-proof” version of OxyContin that uses a “sequestered antagonist” naltrexone in order to stay on top of Oxycontin sales. Why is this important? It’s important because Purdue is unintentionally opening the door for ELTP. ELTP has been researching and developing anti abuse opiates for over 10 years already. It’s also important because it clears all the future competition off the pain market until the respective drug manufactures come up with anti-abuse solutions which has been problematic even for the best of them. For example, Embeda has been recalled : Pfizer’s Anti abuse Morphine Sulfate. Also, their ALO-01 has been recalled.
Reason 2: They have it, it works, and it is an ideal drug as an anti-abuse opiate.
A study published September in the Journal of Psycho-pharmacology 2013 27: 808 J Psychopharmacol notes that a hypothetical ER Naltrexone and Oxycodone product exhibits the least amount of attractiveness, value, likelihood to abuse, overall desirability, and street value.
The first product that ELTP is filing to the FDA in December of 2014 is a Oxycodone Naltrexone formulation.
“Company”) (“Elite”) (ELTP) announced today successful results from a pilot bioequivalence study initiated in December 2013 for ELI-201, a twice-daily opioid abuse deterrent oxycodone product with abuse deterrent technology. Three different twice daily formulations developed by Elite were tested in the study. The study results demonstrate that all formulations in the study were bioequivalent to the reference drug based on pharmacokinetic measures including peak plasma concentration (Cmax) and area under the curve (AUC) for oxycodone blood plasma levels “.
Reason 3: 505(b)(2) and modularity
Elite’s A.R.T. is modular and enables them to apply that anti-abuse tech to multiple drugs. The CEO has expressed in the most recent conference call his desire to file multiple drugs simultaneously and is currently in talks with potential partners.
Drugs approved under 505(b)(2) can rely in part on data from existing reference drugs. This means they can be developed and achieve FDA approval in as little as 30 months with only a fraction of the number of required clinical trials and at much lower cost. The applicant may qualify for three, five, or seven years of market exclusivity, depending on the extent of the change to the previously approved drug and the type of clinical data included in the New Drug Application (NDA).
As soon as ELTP begins to create revenue from their first ART product, the stock should be trading by more than ten dollars. When the other ART drugs begin to get approved 20-30… depending (but not limited to) how big of a market share these guys can take in the chronic pain market. Keep in mind, this stock was 20 dollars when they were selling and making nothing. Why can’t it be there with arguably the best anti-abuse technology hitting the shelves?
Chart
February 24, 2014Leave a reply
« Previous
Leave a Reply
Your email address will not be published. Required fields are marked *
Name *
Email *
Website
Comment
Notify me of new comments via email.
No it's not. It is because we trade on the OTC board. Patience is going to win this battle.
Sellers got burned.
It is sensational!!! Look how cheap these shares are. Cyber Monday discount!!!!!
Exactly. I love this time of the year. Buy your stocks and get ready for the show.
When they file with the FDA the investors and traders will start buying like crazy again. They are just waiting for the news.
It is getting ready for another run. I know I won't be left hanging. Sorry to the ones that are not going to be a part of it. ELTP!
How is hiring three high profile, employees and meeting with the FDA not spectacular. Sorry if you thought the FDA was going to give there stamp of approval already.
Is it over. Td ameritrade shows 0.0000 99.99% loss.
Lol. It is not like Elite sends out PR's for lab techs joining the company.
Wasn't going to work that is.
These three high profile new hires wouldn't join a puny penny stock company if they didn't think the information presented to them was going to work.
nAsRaT will take us to the promise land!!!! ELTP!